Paradigm Biopharmaceuticals Ltd has released a press release.
Paradigm provides regulatory filing update
Filed with ASX ·
6ix hasn’t read this filing yet.
Paradigm Biopharmaceuticals Ltd. on 6ix
Earlier from Paradigm Biopharmaceuticals
- Osteoarthritis pain reduced by Paradigms Zilosul (PPS)
- PAR Expanded Access IND Cleared by US FDA
- Appendix 4E and 2019 Annual Report
- PARs drug reduces cartilage degradation in subjects with OA
- Paradigm files first ind with US FDA
Later from Paradigm Biopharmaceuticals
- Paradigm AGM Presentation
- Paradigm End of Calendar Year Update
- Cleansing Notice and Appendix 3B
- Paradigm presents MPS VI poster at WORLD Symposium
- Paradigm - first patient dosed in USA under FDA approved EAP
Follow Paradigm Biopharmaceuticals into a list and get an email when it puts out news.
Follow Paradigm Biopharmaceuticals